Education
About Us
Working with TipRanks
Follow Us
Prostatype Genomics AB (DE:PGO0)
FRANKFURT:PGO0
PGO0 Stock Chart & Stats
€0.05
-€0.02(-2.92%)
At close: 4:00 PM EST
€0.05
-€0.02(-2.92%)
Day’s Range― - ―
52-Week Range€0.01 - €0.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.50M
Enterprise Value€23.93M
Total Cash (Recent Filing)€12.93M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.44
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding59,189,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€113.90K
Bulls Say, Bears Say
Bulls Say
Focused Precision Diagnostics OfferingA specialised prognostic test that blends molecular biomarkers and clinical data positions the company in a high-value, durable niche of prostate-cancer diagnostics. Per-test revenue and clinical decision support create a product-led business model with recurring clinical demand and defensible commercialization channels over time.
Very Low Financial LeverageNear-zero debt materially reduces refinancing and solvency risk for a loss-making developer of diagnostics. Low leverage extends runway from non-debt financing, preserves strategic optionality for partnerships or R&D investments, and limits fixed financial obligations while commercialization scales.
Reduction In Cash Burn In Latest YearA materially reduced operating cash burn in 2025 signals improving operational efficiency or better per-test economics. While still negative, reduced burn lowers near-term funding pressure, increasing the odds management can reach self-sustaining test volumes or secure less-dilutive partnerships over the medium term.
Bears Say
Deep And Persistent Negative MarginsVery large negative margins indicate the cost base far exceeds current commercialization revenues, a structural issue for a diagnostics business where scale matters. Without marked revenue scale-up or sustained cost reductions, margins will continue to compress equity value and require recurring external funding.
Chronic Negative Operating And Free Cash FlowConsistent negative operating and free cash flow means the company must rely on external financing to sustain operations and invest in commercialization. This constrains strategic flexibility, risks dilution from equity raises, and limits the ability to fund sales expansion or lab partnerships required to scale testing volumes.
Small, Volatile And Recently Declining RevenueLow and inconsistent revenue undermines the economics of a per-test diagnostics model: it impedes fixed-cost absorption and delays margin improvement. A 17% revenue decline in 2025 signals weak commercial traction or market entry issues, making sustainable profitability and cash self-sufficiency more challenging.
PGO0 FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was €0.01 and its highest was €0.20 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is €5.50M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Aug 13, 2026 which is in 153 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Feb 26, 2026. The company reported -€0.037 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.037.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 59,189,320 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -€0.037 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.899%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in DE:PGO0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prostatype Genomics AB
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.